Malignancies Clinical Trials in Chengdu, Sichuan
14 recruitingChengdu, Sichuan, China
Showing 1–14 of 14 trials
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled782 locationsNCT03486873
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Multiple MyelomaHematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.33 enrolled1 locationNCT07255898
Recruiting
Phase 1
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
Solid TumorsImmunotherapyCold Exposure+1 more
West China Hospital24 enrolled1 locationNCT07538479
Recruiting
Phase 1
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
Solid Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.138 enrolled15 locationsNCT06725381
Recruiting
Phase 1
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
Advanced Solid MalignanciesAdvanced Solid Tumor Malignancies
West China Hospital12 enrolled1 locationNCT06927297
Recruiting
Phase 1Phase 2
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting
Phase 1Phase 2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 1Phase 2
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 1
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Hematological Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.191 enrolled22 locationsNCT05728658
Recruiting
Phase 1
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Advanced Solid Tumors and Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.146 enrolled3 locationsNCT05690581
Recruiting
Phase 1Phase 2
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
Advanced Solid TumorAdvanced Solid Malignancies
Zhuhai Yufan Biotechnologies Co., Ltd267 enrolled5 locationsNCT05315167
Recruiting
Early Phase 1
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
Pleural Effusion, MalignantPeritoneal Carcinoma MetastaticHER2 Positive Malignancies
Sichuan University18 enrolled1 locationNCT04684459